Strata Skin Sciences (FRA:E2O) Cyclically Adjusted FCF per Share: €-0.54 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E2O Strata Skin Sciences Inc FRA:E2O
38 GF Score
Price €3.76
GF Value €1,526.56
! 4 Warning Signs
View Full Analysis

What is Strata Skin Sciences Cyclically Adjusted FCF per Share?

Strata Skin Sciences FRA:E2O 38 Cyclically Adjusted FCF per Share is €-0.54 as of Dec. 2025. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €1,526.56. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Strata Skin Sciences's adjusted free cash flow per share for the three months ended in Dec. 2025 was €-0.089. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.54 for the trailing ten years ended in Dec. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 85.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 70.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 44.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Strata Skin Sciences was 85.90% per year. The lowest was 9.00% per year. And the median was 21.90% per year.

As of today (2026-07-25), Strata Skin Sciences's current stock price is €3.76. Strata Skin Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2025 was €-0.54. Strata Skin Sciences's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Strata Skin Sciences was 23.44. The lowest was 13.22. And the median was 16.67.


Strata Skin Sciences  (FRA:E2O) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Strata Skin Sciences was 23.44. The lowest was 13.22. And the median was 16.67.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Strata Skin Sciences Cyclically Adjusted FCF per Share Related Terms


Strata Skin Sciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Strata Skin Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Skin Sciences Cyclically Adjusted FCF per Share Chart

Strata Skin Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -91.37 -59.72 -24.55 -7.35 -0.54

Strata Skin Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.35 -3.60 -1.46 0.16 -0.54

FRA:E2O vs ODYY, NUMD, PFSA: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Strata Skin Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strata Skin Sciences Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Cyclically Adjusted Price-to-FCF falls into.


FRA:E2O
38GF Score
Strata Skin Sciences Inc FRA:E2O
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strata Skin Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Strata Skin Sciences's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-0.089/324.0540*324.0540
=-0.089

Current CPI (Dec. 2025) = 324.0540.

Strata Skin Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 -5.380 238.132 -7.321
201606 -1.190 241.018 -1.600
201609 0.879 241.428 1.180
201612 3.543 241.432 4.755
201703 -0.280 243.801 -0.372
201706 1.339 244.955 1.771
201709 0.641 246.819 0.842
201712 3.506 246.524 4.609
201803 -0.590 249.554 -0.766
201806 -0.398 251.989 -0.512
201809 0.428 252.439 0.549
201812 0.176 251.233 0.227
201903 -0.028 254.202 -0.036
201906 -0.126 256.143 -0.159
201909 0.079 256.759 0.100
201912 -0.083 256.974 -0.105
202003 0.001 258.115 0.001
202006 0.123 257.797 0.155
202009 -0.042 260.280 -0.052
202012 -0.089 260.474 -0.111
202103 -0.146 264.877 -0.179
202106 -0.119 271.696 -0.142
202109 -0.151 274.310 -0.178
202112 -0.119 278.802 -0.138
202203 -0.270 287.504 -0.304
202206 -0.242 296.311 -0.265
202209 -0.355 296.808 -0.388
202212 -0.413 296.797 -0.451
202303 -0.699 301.836 -0.750
202306 -0.200 305.109 -0.212
202309 -0.490 307.789 -0.516
202312 -0.091 306.746 -0.096
202403 -0.401 312.332 -0.416
202406 0.065 314.175 0.067
202409 -0.081 315.301 -0.083
202412 0.046 315.605 0.047
202503 -0.166 319.799 -0.168
202506 -0.391 322.561 -0.393
202509 -0.206 324.800 -0.206
202512 -0.089 324.054 -0.089

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.54 mean?
Strata Skin Sciences (FRA:E2O) has a Cyclically Adjusted FCF per Share of €-0.54 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Strata Skin Sciences and its competitors.
Is Strata Skin Sciences' Cyclically Adjusted FCF per Share too high?
Strata Skin Sciences' current Cyclically Adjusted FCF per Share is €-0.54. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' Cyclically Adjusted FCF per Share compare to ODYY and NUMD?
Strata Skin Sciences' Cyclically Adjusted FCF per Share of €-0.54 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Strata Skin Sciences and its competitors. Strata Skin Sciences's current Cyclically Adjusted FCF per Share is €-0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current Cyclically Adjusted FCF per Share of €-0.54. The stock's GF Value™ is €1,526.56, compared to a current price of €3.76 — trading 99.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.54. Strata Skin Sciences' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current Cyclically Adjusted FCF per Share is €-0.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued. The current stock price of €3.76 is trading 99.8% below its estimated GF Value™ of €1,526.56.

Key valuation signals for FRA:E2O:

  • Cyclically Adjusted FCF per Share: €-0.54
  • GF Value™: €1,526.56 vs. price of €3.76 (99.8% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strata Skin Sciences Business Description

Other Exchanges SSKN:USA
Address 5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score

Get the complete analysis for FRA:E2O

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.76
Price
€1,526.56
GF Value